Short answer
BridgeBio Pharma, Inc. (BBIO) filed its fiscal 2025 10-K annual report with the SEC on Feb 24, 2026. It reported revenue of $502M (+126.3% year over year) and net income of −$725M.
- Top risk flagged: Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience
FY2025 key financial metrics · XBRL
- Revenue
- $502M
- +126.3% YoY
- Net income
- −$725M
- −35.3% YoY
- Operating margin
- -104.2%
- +163.0 pp YoY
- EPS (diluted)
- −$3.78
- −31.3% YoY
- ROE
- 34.7%
- −1.8 pp YoY
- Operating cash flow
- −$446M
- +14.4% YoY
Source: XBRL data from the BridgeBio Pharma, Inc. (BBIO) FY2025 10-K on SEC EDGAR. USD.
BridgeBio Pharma, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Biopharmaceutical development and commercialization with focus on genetic diseases and novel therapies
- New emphasis on commercialization with FDA approval and US launch of Attruby (net product revenue $362.4M in 2025)
- Strategic shift: Exclusive EU license of acoramidis to Bayer and sale of royalty rights generating $300M upfront cash
- Increased SG&A expenses by $242.3M in 2025 supporting commercial launch of Attruby; R&D expenses decreased $54.5M due to program reprioritization
- Raised $619.3M net from 0.75% convertible notes due 2033 in 2026, used partly for common stock repurchase and refinancing debt
Management Discussion & Analysis
- No profitability or margin percentages reported
- No cash flow, buybacks, dividends, or capex figures stated
- Forward-looking risks and uncertainties highlighted, no specific guidance or outlook provided
Risk Factors
- Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience
- Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership
- Board of Directors receives periodic updates on cybersecurity risks and risk management from executive leadership
- Data Privacy and Security Committee meets quarterly to discuss cybersecurity risk management and reports to Audit Committee
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.